{"hands_on_practices": [{"introduction": "When a patient presents with a thrombotic microangiopathy, clinicians face the urgent challenge of distinguishing atypical HUS from its mimic, thrombotic thrombocytopenic purpura (TTP), as treatment differs dramatically. This exercise utilizes the PLASMIC score, a validated clinical prediction tool, to navigate this diagnostic uncertainty. Practicing this calculation helps develop the crucial skill of using pre-test probability to guide life-saving empiric therapy while awaiting definitive diagnostic results [@problem_id:4799984].", "problem": "A $42$-year-old adult presents with acute onset fatigue, easy bruising, and new confusion. Physical examination reveals mild scleral icterus and scattered petechiae. The patient has no history of solid organ or stem cell transplant, and no known or suspected active cancer. There is no history of diarrheal illness. Initial laboratory findings are:\n- Platelet count: $22 \\times 10^{9}$/L\n- Hemoglobin: $9.8$ g/dL\n- Mean corpuscular volume: $88$ fL\n- Lactate dehydrogenase: $1{,}100$ U/L\n- Indirect bilirubin: $2.4$ mg/dL\n- Haptoglobin: undetectable\n- Reticulocyte percentage: $5.1$\n- Creatinine: $2.3$ mg/dL\n- Prothrombin time: $12$ seconds; International normalized ratio: $1.1$\n- Peripheral blood smear: $3+$ schistocytes\n\nA thrombotic microangiopathy due to either thrombotic thrombocytopenic purpura (TTP) or atypical hemolytic uremic syndrome (aHUS) is suspected. The A Disintegrin And Metalloprotease with Thrombospondin type 1 motif, member 13 (ADAMTS13) activity assay has been sent but the result will take $48$–$72$ hours.\n\nUsing the established PLASMIC criteria widely employed to predict severe ADAMTS13 deficiency, assign $1$ point for each of the following present features and $0$ points otherwise:\n- Platelet count $ 30 \\times 10^{9}$/L.\n- Hemolysis variable present (any laboratory evidence of microangiopathic hemolysis such as elevated lactate dehydrogenase, indirect hyperbilirubinemia, undetectable haptoglobin, reticulocytosis, or schistocytosis).\n- No active cancer.\n- No solid organ or stem cell transplant.\n- Mean corpuscular volume $ 90$ fL.\n- International normalized ratio $ 1.5$.\n- Creatinine $ 2.0$ mg/dL.\n\nCompute the total PLASMIC score from the provided data. Then, starting from fundamental pathophysiology of thrombotic microangiopathy and well-tested clinical facts about time-to-result and treatment impact, explain why a high PLASMIC score justifies empiric plasma exchange while ADAMTS13 activity results are pending, explicitly distinguishing the rationale from the management principles of atypical hemolytic uremic syndrome. Provide the PLASMIC score as a pure number with no units; no rounding is required.", "solution": "The problem presented is a clinical vignette requiring the calculation of a diagnostic prediction score and a subsequent explanation of the clinical reasoning based on that score. The validation process is as follows.\n\n### Step 1: Extract Givens\n- **Patient Profile:** $42$-year-old adult.\n- **Clinical Presentation:** Acute onset fatigue, easy bruising, new confusion, mild scleral icterus, scattered petechiae.\n- **Relevant History:** No history of solid organ or stem cell transplant, no known or suspected active cancer, no history of diarrheal illness.\n- **Laboratory Findings:**\n    - Platelet count: $22 \\times 10^{9}$/L\n    - Hemoglobin: $9.8$ g/dL\n    - Mean corpuscular volume (MCV): $88$ fL\n    - Lactate dehydrogenase (LDH): $1{,}100$ U/L\n    - Indirect bilirubin: $2.4$ mg/dL\n    - Haptoglobin: undetectable\n    - Reticulocyte percentage: $5.1\\%$\n    - Creatinine: $2.3$ mg/dL\n    - Prothrombin time: $12$ seconds; International normalized ratio (INR): $1.1$\n    - Peripheral blood smear: $3+$ schistocytes\n- **Diagnostic Context:** Suspected thrombotic microangiopathy (TMA), specifically thrombotic thrombocytopenic purpura (TTP) versus atypical hemolytic uremic syndrome (aHUS). A Disintegrin And Metalloprotease with Thrombospondin type 1 motif, member 13 (ADAMTS13) activity assay is pending with a $48$–$72$ hour turnaround time.\n- **Scoring System (PLASMIC score):** Assign $1$ point for each feature present, $0$ otherwise.\n    1. Platelet count $ 30 \\times 10^{9}$/L.\n    2. Hemolysis variable present (any evidence of microangiopathic hemolysis).\n    3. No active cancer.\n    4. No solid organ or stem cell transplant.\n    5. MCV $ 90$ fL.\n    6. INR $ 1.5$.\n    7. Creatinine $ 2.0$ mg/dL.\n- **Task:** Compute the total PLASMIC score. Explain why a high score justifies empiric plasma exchange while awaiting ADAMTS13 results, distinguishing the rationale from the management of aHUS.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established validation criteria.\n- **Scientifically Grounded:** The problem is firmly grounded in established medical science, specifically hematology and nephrology. The clinical presentation, laboratory values, and differential diagnosis are classic for TMAs. The PLASMIC score is a validated and widely used clinical decision rule. The pathophysiology of TTP and aHUS, the role of ADAMTS13, and the mechanisms of plasma exchange and complement inhibition are all core, evidence-based medical concepts. The problem is an excellent representation of a real-world clinical scenario.\n- **Well-Posed:** The problem is clearly stated. All data required to calculate the PLASMIC score are provided. The request for a pathophysiological explanation is specific and directs the line of reasoning. A unique numerical answer and a logically sound explanation can be derived directly from the givens.\n- **Objective:** The problem is based on objective laboratory data and explicit, non-ambiguous criteria for the scoring system. It is free from subjective or opinion-based statements.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. It is scientifically sound, well-posed, objective, and represents a non-trivial application of medical knowledge and quantitative reasoning. I will proceed with the solution.\n\n### Solution Derivation\n\nThe solution is in two parts: calculation of the PLASMIC score and the subsequent clinical-pathophysiological explanation.\n\n**Part 1: PLASMIC Score Calculation**\n\nThe total score is the sum of points from the $7$ criteria, where each criterion is assigned $1$ point if true and $0$ if false.\n\n1.  **Platelet count $ 30 \\times 10^{9}$/L:** The patient's platelet count is $22 \\times 10^{9}$/L. Since $22  30$, this criterion is met. **Points = $1$**.\n2.  **Hemolysis variable present:** The problem defines this as \"any laboratory evidence of microangiopathic hemolysis\". The patient exhibits multiple signs: elevated LDH ($1{,}100$ U/L), elevated indirect bilirubin ($2.4$ mg/dL), undetectable haptoglobin, reticulocytosis ($5.1\\%$), and schistocytes on the peripheral smear. The presence of any one of these is sufficient. This criterion is met. **Points = $1$**.\n3.  **No active cancer:** The problem explicitly states, \"no known or suspected active cancer\". This criterion is met. **Points = $1$**.\n4.  **No solid organ or stem cell transplant:** The problem explicitly states, \"no history of solid organ or stem cell transplant\". This criterion is met. **Points = $1$**.\n5.  **Mean corpuscular volume (MCV) $ 90$ fL:** The patient's MCV is $88$ fL. Since $88  90$, this criterion is met. **Points = $1$**.\n6.  **International normalized ratio (INR) $ 1.5$:** The patient's INR is $1.1$. Since $1.1  1.5$, this criterion is met. This finding helps to exclude other causes of consumptive coagulopathy like severe disseminated intravascular coagulation (DIC). **Points = $1$**.\n7.  **Creatinine $ 2.0$ mg/dL:** The patient's creatinine is $2.3$ mg/dL. Since $2.3$ is not less than $2.0$, this criterion is not met. **Points = $0$**.\n\nThe total PLASMIC score is the sum of the points:\nTotal Score $= 1 + 1 + 1 + 1 + 1 + 1 + 0 = 6$.\n\n**Part 2: Rationale for Empiric Plasma Exchange**\n\nA PLASMIC score of $6$ indicates a high probability of severe ADAMTS13 deficiency (activity $10\\%$), the defining feature of thrombotic thrombocytopenic purpura (TTP). The justification for initiating empiric plasma exchange (PEX) is based on the fundamental pathophysiological differences between TTP and atypical hemolytic uremic syndrome (aHUS), the time-critical nature of TTP, and the mechanism of action of PEX.\n\n**Pathophysiology of TTP vs. aHUS:**\nBoth TTP and aHUS are forms of thrombotic microangiopathy (TMA), a pathological process of microvascular thrombosis leading to consumptive thrombocytopenia, microangiopathic hemolytic anemia (MAHA), and end-organ ischemia. However, their underlying causes are distinct.\n\n-   **TTP Pathophysiology:** TTP is caused by a severe deficiency of the enzyme ADAMTS13. In most adult cases, this is due to inhibitory autoantibodies. ADAMTS13 is a metalloprotease responsible for cleaving ultra-large von Willebrand factor (vWF) multimers into smaller, less thrombogenic forms. In its absence, these ultra-large vWF multimers persist in circulation. They are hyperactive, spontaneously binding to platelets and causing widespread, platelet-rich microthrombi to form, particularly under high shear stress conditions found in the microvasculature. This leads to profound thrombocytopenia and organ damage, with a predilection for the brain (causing neurological symptoms like confusion) and heart. Untreated, TTP has a mortality rate exceeding $90\\%$.\n\n-   **aHUS Pathophysiology:** aHUS is caused by chronic, uncontrolled activation of the alternative complement pathway on endothelial cell surfaces. This is typically due to genetic mutations in complement regulatory proteins or autoantibodies against complement factor H. The dysregulated complement cascade leads to endothelial injury, inflammation, and the formation of fibrin-and-platelet-rich thrombi. While it can affect any organ, this process has a strong predilection for the renal microvasculature, often leading to severe acute kidney injury and progression to end-stage renal disease. The patient's creatinine of $2.3$ mg/dL, which is elevated but not consistent with the most severe forms of renal failure, makes the diagnosis ambiguous; however, the fact that creatinine is $\\geq 2.0$ mg/dL is the one feature pointing more towards aHUS than TTP, lowering the PLASMIC score from a perfect $7$ to $6$.\n\n**The Clinical Dilemma and the Role of the PLASMIC Score:**\nThe clinical presentations can overlap significantly, as seen in this case. The definitive diagnosis relies on the ADAMTS13 activity level, but the test result is not immediately available. TTP is a medical emergency where immediate intervention is life-saving. A delay of $48$–$72$ hours to await the ADAMTS13 result before starting treatment would expose a patient with true TTP to an unacceptably high risk of death or irreversible ischemic organ damage (e.g., stroke).\n\nThe PLASMIC score quantifies the pre-test probability of TTP. A score of $6$–$7$ is classified as high-risk, corresponding to a $70\\%$ probability of severe ADAMTS13 deficiency. This high probability transforms the clinical uncertainty into a rational basis for action.\n\n**Rationale for Empiric PEX in High-Probability TTP:**\nThe first-line treatment for TTP is PEX. PEX has a dual therapeutic mechanism perfectly tailored to the pathophysiology of acquired TTP:\n1.  **Removal of Pathogen:** It removes the causative agent, which are the circulating anti-ADAMTS13 autoantibodies.\n2.  **Replenishment of Deficient Factor:** It replenishes the deficient enzyme (ADAMTS13) by infusing fresh frozen plasma from healthy donors.\n\nGiven a PLASMIC score of $6$, the decision is to treat for the most probable and most imminently lethal diagnosis. The principle is to initiate empiric PEX immediately. The considerable benefit of preventing death and major disability in a patient with TTP far outweighs the risks of performing PEX (e.g., central line complications, allergic reactions) on a patient who may ultimately be diagnosed with aHUS.\n\n**Contrasting with aHUS Management:**\nThe definitive treatment for aHUS is not PEX, but rather targeted inhibition of the complement pathway with monoclonal antibodies like eculizumab. While PEX was used for aHUS before complement inhibitors were developed, its efficacy is poor as it only transiently removes complement factors and provides a limited amount of functional regulators. For aHUS, the critical intervention is to block the C5 component of the complement cascade. Therefore, if the ADAMTS13 activity level returns as normal ($10\\%$), TTP is excluded. PEX would be discontinued, and therapy would be switched to a complement inhibitor to treat the presumptive diagnosis of aHUS.\n\nIn summary, a high PLASMIC score of $6$ provides a sufficiently strong statistical and clinical justification to bridge the diagnostic gap. It mandates immediate, empiric treatment with PEX for presumptive TTP, a condition where time-to-treatment is the most critical determinant of outcome, while clearly understanding that this strategy will be revised once the definitive ADAMTS13 result is available.", "answer": "$$\\boxed{6}$$", "id": "4799984"}, {"introduction": "Acute kidney injury is a defining and severe complication of hemolytic uremic syndrome, making the accurate assessment of renal function a cornerstone of patient management. This practice focuses on quantifying kidney damage by calculating the estimated glomerular filtration rate (eGFR) using the updated bedside Schwartz equation, a standard tool in pediatrics. Mastering this calculation is essential for staging the severity of kidney injury and tracking the patient's response to supportive care [@problem_id:5150727].", "problem": "A $9$-year-old child is admitted with diarrhea-associated hemolytic uremic syndrome (HUS), characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. The estimated glomerular filtration rate (eGFR) is to be determined as part of renal function assessment. The child’s height is measured as $130 \\ \\mathrm{cm}$, and the serum creatinine (SCr) is $0.8 \\ \\mathrm{mg/dL}$, measured by an enzymatic assay calibrated to isotope dilution mass spectrometry (IDMS). Use the updated bedside Schwartz approach appropriate for pediatric patients to compute the eGFR normalized to $1.73 \\ \\mathrm{m^2}$.\n\nStarting from first principles that link creatinine clearance to glomerular filtration rate and the observed inverse relationship between serum creatinine and filtration, and recognizing the empirical length scaling used in pediatrics, identify the appropriate age/sex-dependent proportionality constant in the updated bedside approach and compute the eGFR for this patient.\n\nRound your final numeric answer to three significant figures and express it in $\\mathrm{mL/min/1.73 \\ m^2}$.", "solution": "The problem is assessed to be valid. It is scientifically grounded in pediatric nephrology, well-posed with sufficient and consistent data, and objectively stated. The values provided for the patient's age ($9$ years), height ($130 \\ \\mathrm{cm}$), and serum creatinine ($0.8 \\ \\mathrm{mg/dL}$) are clinically plausible for a child with acute kidney injury secondary to hemolytic uremic syndrome. The problem correctly specifies the use of the updated bedside Schwartz formula, which is appropriate given that the serum creatinine measurement is calibrated to isotope dilution mass spectrometry (IDMS).\n\nThe estimation of glomerular filtration rate (eGFR) is a cornerstone of assessing kidney function. The gold standard, measurement of inulin clearance, is invasive and not practical for routine clinical settings. Therefore, eGFR is typically estimated using endogenous filtration markers.\n\nThe fundamental principle of clearance states that for a substance $X$, its clearance $C_X$ from the plasma is given by:\n$$\nC_X = \\frac{U_X \\cdot V}{P_X}\n$$\nwhere $U_X$ is the urinary concentration of the substance, $V$ is the urine flow rate, and $P_X$ is the plasma concentration of the substance.\n\nCreatinine, a metabolic byproduct of creatine phosphate in muscle, is used as such an endogenous marker. It is produced at a relatively constant rate, proportional to muscle mass, and is freely filtered by the glomerulus with minimal tubular secretion. Therefore, creatinine clearance ($C_{Cr}$) provides a reasonable approximation of the GFR. Under steady-state conditions, the rate of creatinine production (and thus urinary excretion) is constant.\n$$\n\\text{Rate of Excretion} = U_{Cr} \\cdot V = C_{Cr} \\cdot P_{Cr}\n$$\nAssuming $C_{Cr} \\approx \\text{GFR}$ and letting $P_{Cr}$ be the serum creatinine (SCr), we have:\n$$\n\\text{Rate of Production} \\approx \\text{GFR} \\cdot \\text{SCr}\n$$\nThis establishes the inverse relationship between GFR and SCr: $\\text{GFR} \\propto \\frac{1}{\\text{SCr}}$.\n\nIn the pediatric population, muscle mass is not constant but scales with body size. Body height (or length) is used as a surrogate for muscle mass. Combining these relationships, the rate of creatinine production is proportional to height. Therefore, the estimation of GFR takes the general form:\n$$\n\\text{eGFR} \\propto \\frac{\\text{Height}}{\\text{SCr}}\n$$\nThis is the basis for the Schwartz formula, where the proportionality is resolved by an empirical constant, $k$:\n$$\n\\text{eGFR} = \\frac{k \\cdot \\text{Height}}{\\text{SCr}}\n$$\nThe problem specifies the use of the \"updated bedside Schwartz approach\" and an IDMS-traceable serum creatinine assay. The original Schwartz formula used different $k$ values based on age and sex. However, in $2009$, Schwartz et al. published an updated formula, often called the \"bedside Schwartz formula,\" specifically for use with modern, more accurate IDMS-traceable enzymatic creatinine assays. A key feature of this updated formula is the use of a single, unified constant for children and adolescents aged $1$ to $16$ years, simplifying its application.\n\nThe appropriate constant, $k$, for the updated bedside Schwartz formula is $0.413$. While the prompt text refers to an \"age/sex-dependent\" constant, this reflects the structure of the older formulas. The \"updated bedside approach\" itself simplifies this by using a single constant for the patient's age group.\n\nThe formula to be used is:\n$$\n\\text{eGFR} \\ (\\text{in} \\ \\mathrm{mL/min/1.73 \\ m^2}) = \\frac{0.413 \\cdot \\text{Height} \\ (\\text{in} \\ \\mathrm{cm})}{\\text{SCr} \\ (\\text{in} \\ \\mathrm{mg/dL})}\n$$\nThe given values for the patient are:\n- Height = $130 \\ \\mathrm{cm}$\n- Serum Creatinine (SCr) = $0.8 \\ \\mathrm{mg/dL}$\n- Constant ($k$) = $0.413$\n\nSubstituting these values into the equation:\n$$\n\\text{eGFR} = \\frac{0.413 \\cdot 130}{0.8}\n$$\nFirst, calculate the numerator:\n$$\n0.413 \\cdot 130 = 53.69\n$$\nNow, perform the division:\n$$\n\\text{eGFR} = \\frac{53.69}{0.8} = 67.1125\n$$\nThe problem requires the final answer to be rounded to three significant figures. The calculated value is $67.1125 \\ \\mathrm{mL/min/1.73 \\ m^2}$. Rounding this to three significant figures gives $67.1$.\n\nThis value indicates a significant reduction in kidney function (normal eGFR is typically considered $ 90 \\ \\mathrm{mL/min/1.73 \\ m^2}$), which is consistent with the diagnosis of acute kidney injury in the context of HUS.", "answer": "$$\n\\boxed{67.1}\n$$", "id": "5150727"}, {"introduction": "The advent of complement inhibitors has revolutionized the treatment of atypical HUS, shifting the prognosis for this once-devastating disease. This exercise simulates the practical application of eculizumab, a C5 monoclonal antibody, for a pediatric patient, requiring calculation of the correct dosing schedule and integration of essential safety protocols. This practice provides hands-on experience with the complexities of administering modern biologic therapies, from weight-based dosing to mandatory risk mitigation strategies [@problem_id:5150687].", "problem": "A child with atypical Hemolytic Uremic Syndrome (aHUS) weighing $25$ kilograms requires initiation of eculizumab therapy. Eculizumab is a humanized monoclonal antibody that binds Complement Component $5$ (C5) and prevents terminal complement activation, thereby increasing the risk of invasive disease due to Neisseria meningitidis. It is a well-tested fact that to mitigate this risk, quadrivalent meningococcal conjugate vaccine against serogroups A, C, W, and Y (MenACWY) and serogroup B meningococcal vaccine (MenB) should be administered at least $14$ days before the first dose of a terminal complement inhibitor; if urgent therapy must begin earlier, antibiotic prophylaxis should be provided to cover the interval before vaccine-induced protection is expected.\n\nAccording to United States Food and Drug Administration (FDA) labeling for atypical Hemolytic Uremic Syndrome (aHUS), children with body weight in the interval $20 \\leq W  30$ kilograms receive eculizumab at a per-dose amount of $600$ milligrams. The induction phase consists of $2$ weekly doses, followed by maintenance dosing of $600$ milligrams every $2$ weeks thereafter, beginning one week after the last induction dose.\n\nAssume the following clinically realistic constraints:\n- Therapy must start urgently at week $1$ (day $0$ of the treatment timeline), and both MenACWY and MenB vaccines are administered on day $0$.\n- Antibiotic prophylaxis is required because therapy begins less than $14$ days after vaccination; prophylaxis should cover the interval until at least $14$ days have elapsed after vaccination.\n\nCompute the cumulative eculizumab dose administered over the first $12$ weeks of therapy, assuming all scheduled doses are given on time starting at week $1$. In your reasoning, specify the appropriate meningococcal vaccine timing and the antibiotic prophylaxis interval relative to the start of therapy and vaccination. Express the final cumulative dose in milligrams and round your answer to four significant figures.", "solution": "The user has provided a problem statement that requires validation before a solution is attempted.\n\n### Step 1: Extract Givens\n- **Patient**: A child with atypical Hemolytic Uremic Syndrome (aHUS).\n- **Weight ($W$)**: $25$ kilograms.\n- **Drug**: Eculizumab, a humanized monoclonal antibody that binds Complement Component $5$ (C5).\n- **Associated Risk**: Invasive disease due to *Neisseria meningitidis*.\n- **Risk Mitigation - Vaccination**: Quadrivalent meningococcal conjugate vaccine (MenACWY) and serogroup B meningococcal vaccine (MenB) should be administered at least $14$ days before the first dose of a terminal complement inhibitor.\n- **Risk Mitigation - Prophylaxis**: If therapy begins earlier than $14$ days post-vaccination, antibiotic prophylaxis is required to cover the interval until vaccine-induced protection is expected.\n- **FDA Dosing for aHUS (Weight-based)**: For body weight in the interval $20 \\leq W  30$ kilograms, the per-dose amount is $600$ milligrams.\n- **Dosing Schedule - Induction**: $2$ weekly doses.\n- **Dosing Schedule - Maintenance**: $600$ milligrams every $2$ weeks, beginning one week after the last induction dose.\n- **Assumed Constraint 1**: Therapy starts urgently at week $1$ (day $0$ of the treatment timeline).\n- **Assumed Constraint 2**: MenACWY and MenB vaccines are administered on day $0$.\n- **Assumed Constraint 3**: Antibiotic prophylaxis is required and should cover the interval until at least $14$ days have elapsed after vaccination.\n- **Computational Task**: Compute the cumulative eculizumab dose administered over the first $12$ weeks of therapy.\n- **Reporting Task 1**: Specify the meningococcal vaccine timing and the antibiotic prophylaxis interval.\n- **Reporting Task 2**: Express the final cumulative dose in milligrams, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the established criteria.\n- **Scientifically Grounded**: The problem is factually sound. The use of eculizumab for aHUS, its mechanism of action (C5 inhibition), the associated increased risk of meningococcal disease, and the described risk mitigation strategies (vaccination with MenACWY and MenB, and antibiotic prophylaxis for urgent starts) are all consistent with established medical guidelines and clinical practice. The FDA-approved pediatric dosing regimen cited for the child's weight class is accurate.\n- **Well-Posed**: The problem is well-posed. It provides all necessary information to calculate the cumulative dose: patient weight, dose per administration, a precise induction and maintenance schedule, and a specific timeframe for the calculation ($12$ weeks). The question has a unique and determinable numerical answer.\n- **Objective**: The problem is stated in objective, clinical language, free of bias or subjective claims.\n- **Internal Consistency**: The constraints are consistent. The urgent start of therapy on day $0$ combined with vaccination on day $0$ correctly implies the need for antibiotic prophylaxis as stated, creating a logically sound clinical scenario.\n- **Flaws**: The problem does not exhibit any of the flaws listed in the validation checklist. It is not scientifically unsound, non-formalizable, incomplete, unrealistic, ill-posed, or trivial.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be provided.\n\nThe problem requires a calculation of the total dose of eculizumab administered over a $12$-week period and a specification of the vaccination and prophylaxis timeline.\n\nFirst, the vaccination and prophylaxis timeline will be established based on the provided constraints.\nTherapy starts on day $0$. The MenACWY and MenB vaccines are also administered on day $0$. According to the problem statement, antibiotic prophylaxis is required if therapy begins less than $14$ days after vaccination. Since therapy and vaccination occur on the same day (day $0$), this condition is met. The prophylaxis must cover the interval \"until at least $14$ days have elapsed after vaccination.\" Therefore, antibiotic prophylaxis must be administered from day $0$ through at least day $14$ of the treatment course.\n\nSecond, the cumulative dose of eculizumab over the first $12$ weeks of therapy will be calculated. The dosing regimen is divided into an induction phase and a maintenance phase. Let the dose per administration be $D_{dose} = 600$ mg. The total duration of interest is the first $12$ weeks, which corresponds to days $0$ through $83$ ($12 \\text{ weeks} \\times 7 \\text{ days/week} - 1 \\text{ day}$).\n\nThe dosing schedule is constructed as follows, with week $1$ starting on day $0$:\n- **Induction Phase**: Consists of $2$ weekly doses.\n  - Dose $1$: Administered at the start of Week $1$ (Day $0$). Dose = $600$ mg.\n  - Dose $2$: Administered at the start of Week $2$ (Day $7$). Dose = $600$ mg.\nThe last induction dose is given on Day $7$.\n\n- **Maintenance Phase**: Begins one week after the last induction dose, with doses administered every $2$ weeks.\n  - The first maintenance dose is administered one week after Day $7$, which is Day $14$ (start of Week $3$).\n  - Subsequent maintenance doses are given every $2$ weeks (every $14$ days). The schedule of maintenance doses within the first $12$ weeks is:\n    - Dose $3$: Day $14$ (Week $3$). Dose = $600$ mg.\n    - Dose $4$: Day $14+14 = 28$ (Week $5$). Dose = $600$ mg.\n    - Dose $5$: Day $28+14 = 42$ (Week $7$). Dose = $600$ mg.\n    - Dose $6$: Day $42+14 = 56$ (Week $9$). Dose = $600$ mg.\n    - Dose $7$: Day $56+14 = 70$ (Week $11$). Dose = $600$ mg.\n  - The next scheduled dose would be on Day $70+14 = 84$. This day falls at the beginning of Week $13$ and is outside the specified time frame of the \"first $12$ weeks\" (Days $0$-$83$).\n\nThe total number of doses administered during the first $12$ weeks is the sum of induction and maintenance doses.\nNumber of induction doses, $N_{ind} = 2$.\nNumber of maintenance doses, $N_{maint} = 5$.\nTotal number of doses, $N_{total} = N_{ind} + N_{maint} = 2 + 5 = 7$.\n\nThe cumulative dose, $D_{cumulative}$, is the total number of doses multiplied by the dose per administration.\n$$D_{cumulative} = N_{total} \\times D_{dose}$$\n$$D_{cumulative} = 7 \\times 600 \\text{ mg}$$\n$$D_{cumulative} = 4200 \\text{ mg}$$\n\nThe problem requires the answer to be rounded to four significant figures. The calculated value is exactly $4200$. This value can be expressed with four significant figures as $4.200 \\times 10^3$, or simply as $4200$ where the trailing zeros are understood to be significant in this context. The value $4200$ inherently satisfies the precision requirement without needing to be altered.\n\nSummary of findings:\n- **Vaccine Timing**: MenACWY and MenB vaccines are administered on day $0$.\n- **Antibiotic Prophylaxis Interval**: Required from day $0$ through at least day $14$.\n- **Cumulative Eculizumab Dose**: $4200$ mg.", "answer": "$$\n\\boxed{4200}\n$$", "id": "5150687"}]}